Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo : Effects on Cardiac Fibrosis and Hypertrophy
Joint Authors
Veeraveedu, Punniyakoti T.
Suzuki, Kenji
Mito, Sayaka
Thandavarayan, Rajarajan A.
Watanabe, Kenichi
Kobayashi, Yoshiyasu
Arumugam, Somasundaram
Ma, Meilei
Soetikno, Vivian
Arozal, Wawaimuli
Lakshmanan, Arun Prasath
Sari, Flori R.
Sukumaran, Vijayakumar
Source
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-04-14
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Pharmacy, Health & Medical Sciences
Pharmacology
Abstract EN
Anthracyclines, most powerful anticancer agents, suffer from their cardiotoxic effects, which may be due to the induction of oxidative stress.
Carvedilol, a third-generation, nonselective β-adrenoreceptor antagonist, possesses both reactive oxygen species (ROS) scavenging and ROS suppressive effects.
It showed protective effects against daunorubicin- (DNR-) induced cardiac toxicity by reducing oxidative stress and apoptosis.
This study therefore was designed to examine the effects of carvedilol on DNR-induced cardiomyopathic rats, focused on the changes of left ventricular function, cardiac fibrosis, and hypertrophy.
Carvedilol increased survival rate, prevented systolic and diastolic dysfunction, and attenuated myocardial fibrosis and hypertrophy.
DNR alone treated rats showed upregulated myocardial expression of ANP, PKC-α, OPN, and TGF-β1 and downregulation of GATA-4 in comparison with control, and treatment with carvedilol significantly reversed these changes.
The results of the present study add the available evidences on the cardioprotection by carvedilol when associated with anthracyclines and explain the mechanisms underlying the benefits of their coadministration.
American Psychological Association (APA)
Arozal, Wawaimuli& Sari, Flori R.& Watanabe, Kenichi& Arumugam, Somasundaram& Veeraveedu, Punniyakoti T.& Ma, Meilei…[et al.]. 2011. Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo : Effects on Cardiac Fibrosis and Hypertrophy. ISRN Pharmacology،Vol. 2011, no. 2011, pp.1-8.
https://search.emarefa.net/detail/BIM-471679
Modern Language Association (MLA)
Arozal, Wawaimuli…[et al.]. Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo : Effects on Cardiac Fibrosis and Hypertrophy. ISRN Pharmacology No. 2011 (2011), pp.1-8.
https://search.emarefa.net/detail/BIM-471679
American Medical Association (AMA)
Arozal, Wawaimuli& Sari, Flori R.& Watanabe, Kenichi& Arumugam, Somasundaram& Veeraveedu, Punniyakoti T.& Ma, Meilei…[et al.]. Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo : Effects on Cardiac Fibrosis and Hypertrophy. ISRN Pharmacology. 2011. Vol. 2011, no. 2011, pp.1-8.
https://search.emarefa.net/detail/BIM-471679
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-471679